Study aim: The effect of curcumin on oxidant , antioxidant factors , liver ,kidney tests serum , clinical signs and symptoms of multiple sclerosis patients Design: Clinical practice with control group, parallel, double-blind, randomized, phase 3 over 96 patients, blocked randomization method Settings and conduct: The clinics of Arak University of Medical Sciences will be double-blind and patients will be divided into two groups of cases and Dronoma as blocked randomization with 4 and 6 block sizes. The doctor's secretary (who has no knowledge of the type of capsules and the group of patients in which they are placed) will be given. Thus, the researcher, the specialist, the patient will be blinded. Participants/Inclusion and exclusion criteria: Ms have RRMS, age 18 to 50, and EDSS (less than 4). Patients who have been diagnosed with MS for at least a year have no gastrointestinal problems. Don't take zinc supplements or selenium supplements. Anthocyanin-like corticosteroids, such as vitamin EA-D, haven't been used for at least the past two weeks. Don't be pregnant. Don't be breastfeeding women Intervention groups: Razak 270 mg Corkomine Capsule, Stanoma Pharma Capsule Capsule Main outcome variables: Total Oxidative Capacity, Oxygenated Water, Malondialdehyde, Revitalizing Glutathione, Dysmotaz Super Oxide, Alanine Amino Transfer, Aspartate Amino Transfer, Nitrogen Urea Blood, Blood Creatinine, Fatigue, gait disorders and severe disability